Synapse - Combination olaparib and temozolomide for the treatment of glioma: A retrospective case series

Combination olaparib and temozolomide for the treatment of glioma: A retrospective case series Journal Article

Authors:	Schaff, L. R.; Kushnirsky, M.; Lin, A. L.; Nandakumar, S.; Grommes, C.; Miller, A. M.; Gavrilovic, I. T.; Nolan, C.; Pentsova, E.; Mellinghoff, I. K.; Kaley, T. J.
Article Title:	Combination olaparib and temozolomide for the treatment of glioma: A retrospective case series
Abstract:	Background and ObjectivesTo report the tolerability and efficacy of olaparib with temozolomide (TMZ) for glioma.MethodsSingle-center retrospective series of patients with glioma treated with olaparib/TMZ from September 2018 to December 2021.ResultsTwenty patients (median age: 42 years, median Karnofsky Performance Status: 90) received olaparib/TMZ for diagnoses of IDH-mutant oligodendroglioma (n = 5), IDH-mutant astrocytoma grade 2-3 (n = 4), IDH-mutant astrocytoma grade 4 (n = 7), or IDH-wildtype glioma (n = 4). One patient was treated upfront and 19 at recurrence (median = 3). Olaparib 150 mg was administered 3 times/week concurrent with TMZ 50-75 mg/m2 daily. Fatigue, gastrointestinal symptoms, and hematologic toxicity were common. Six of 20 patients required dose reduction (n = 4) or discontinuation (n = 2) due to toxicity. Radiographic response was evaluable in 16 and observed (complete + partial) in 4/8 with IDH-mutant grade 2-3 glioma. No responses were seen in patients with grade 4 IDH-mutant astrocytomas (0/5) or IDH-wildtype gliomas (0/3). Progression-free survival was 7.8, 1.3, and 2.0 months, respectively.DiscussionOlaparib/TMZ resulted in objective radiographic response in 50% of evaluable patients with recurrent IDH-mutant grade 2-3 gliomas with encouraging progression-free survival and manageable toxicity. This supports a prospective trial of olaparib/TMZ for this population.Classification of EvidenceThis case series provides Class IV evidence that treatment with olaparib/TMZ may result in radiographic response in patients with glioma. © American Academy of Neurology.
Journal Title:	Neurology
Volume:	99
Issue:	17
ISSN:	0028-3878
Publisher:	Lippincott Williams & Wilkins
Date Published:	2022-10-25
Start Page:	750
End Page:	755
Language:	English
DOI:	10.1212/wnl.0000000000201203
PUBMED:	35948444
PROVIDER:	scopus
PMCID:	PMC9620814
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141254420&doi=10.1212%2fWNL.0000000000201203&partnerID=40&md5=70b4a4c6c875cff64c1dbf3c24ac931f
Notes:	Article -- Export Date: 1 December 2022 -- Source: Scopus